Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

374
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
374
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.1K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.1K
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

78
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
78
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

119
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
119
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

195
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
195
One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution01:09

One-Compartment Open Model for IV Bolus Administration: Estimation of Elimination Rate Constant, Half-Life and Volume of Distribution

484
The one-compartment open model is a simplified approach used in pharmacokinetics to understand the distribution and elimination of a drug administered through an intravenous bolus. This model assumes rapid drug dispersal throughout the body and elimination using a first-order process. Key pharmacokinetic parameters, such as the elimination rate constant (k), half-life (t1/2), and the apparent volume of distribution (Vd), can be estimated from this model. The elimination rate is calculated...
484

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repeat CRP measurements and incident myocardial infarction.

American journal of preventive cardiology·2026
Same author

Enhancing the Sensitivity of Mass Spectrometry Imaging through Spatial Signal Averaging.

Journal of the American Society for Mass Spectrometry·2026
Same author

Shifting a paradigm: highlights of model informed drug development in dosage selection and optimization for oncology products.

The oncologist·2026
Same author

PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4<sup>+</sup> lymphocytes.

British journal of clinical pharmacology·2026
Same author

Population Pharmacokinetics and Dosing Simulations of Pentobarbital in the Pediatric Population.

Journal of clinical pharmacology·2026
Same author

Shifting a paradigm: highlights of model informed drug development in dosage selection and optimization for oncology products.

The oncologist·2026

Related Experiment Video

Updated: Sep 5, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.9K

Leveraging a Previously Published Population Pharmacokinetic Model to Predict Rivaroxaban Exposure in Real-World

Daniel Weiner1, J Robert Powell1, J Herbert Patterson1

  • 1Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Journal of Clinical Pharmacology
|July 9, 2022
PubMed
Summary

Rivaroxaban dosing may not ensure optimal exposure for individual real-world patients, despite label recommendations. A population pharmacokinetic model showed variability in predicting drug exposure, highlighting potential dosing challenges.

Keywords:
population pharmacokineticsprecision dosingrivaroxaban

More Related Videos

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.4K
Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

1.4K

Related Experiment Videos

Last Updated: Sep 5, 2025

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

13.9K
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.4K
Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

1.4K

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Drug Dosing and Exposure

Background:

  • Population pharmacokinetic (PK)/pharmacodynamic models are crucial for drug dosing but may not represent real-world patient populations accurately.
  • Discrepancies between clinical trial populations and real-world patients can lead to suboptimal drug exposure.
  • Rivaroxaban dosing recommendations require evaluation for their effectiveness in diverse patient groups.

Purpose of the Study:

  • To assess the accuracy of a published rivaroxaban population PK model in predicting drug exposure for real-world patients.
  • To evaluate if standard rivaroxaban labeling achieves therapeutic exposure (Area Under the Curve [AUC]) in real-world individuals.
  • To compare different methods of utilizing the PK model for exposure prediction.

Main Methods:

  • Utilized a prior rivaroxaban population PK model to predict exposure in 230 real-world patients.
  • Employed three prediction methods: phenotype data only, post hoc clearance estimates without model refitting, and post hoc clearance estimates after model refitting.
  • Compared predictions across three software packages: NONMEM, Phoenix NLME, and Monolix.

Main Results:

  • While average patient dosing aligns with label recommendations and falls within the reference AUC range, most individual patients experienced AUC outside this range.
  • Post hoc estimates showed minor average differences (<10%) between software packages, but individual estimates varied significantly (up to 50%).
  • The study confirmed the utility of a prior PK model for predicting real-world rivaroxaban exposure.

Conclusions:

  • Rivaroxaban drug label dosing may not guarantee therapeutic AUC for all individual real-world patients.
  • Population PK models can predict real-world exposure, but methods for individualizing predictions require careful consideration.
  • Variability in individual patient PK necessitates refined approaches to ensure optimal rivaroxaban dosing.